Molecular imaging using the 5-HT2A agonist PET ligand [11C]CIMBI-36 can help elucidate the links between psychedelic dose and acute or longer-term clinically-relevant effects.

Authors

• Person: Not available Organization: Nature
  Neuroimaging in psychedelic drug development: past, present, and ...

Sources

• Neuroimaging in psychedelic drug development: past, present, and ... www.nature.com Nature via serper

Referenced by nodes (1)

• PET concept